Skip to content
Screener

Common Stock at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$292M0.0%
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
130M0.0%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$2.43B+65.2%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
150M0.0%
Biohaven logo
BiohavenBHVN
200M0.0%
Septerna, Inc. logo
Septerna, Inc.SEPN
$46K+2.2%

Other financials

Income statement

See full
Revenue-
Operating income-$60.8M-106%
Net income-$56.6M-112%
EPS (diluted)-$1.19-58.7%

Balance sheet

See full
Cash & equivalents$63.6M+15.5%
Total debt$10.1M-14.8%
Total equity$422.9M+60.5%
Total assets$459.0M+60.8%

Cash flow

See full
Operating cash flow-$41.5M-65.4%
CapEx$78.0K+255%
Free cash flow-$41.5M-65.5%

Valuation

See full
Market cap$2.18B+319%
Enterprise value$2.13B+345%
P/S109.1×

Profitability

See full
Operating margin-767.6%
Net margin-685.8%
FCF margin-485.7%

Returns & leverage

See full
Return on equity-40%+22.3pp
Debt / equity0.0×
Current ratio15.7×-7.0×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:30 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333862
Line itemJune 30,2026December 31,2025
Commitments and contingencies (Note 10)
Stockholders’ equity
Undesignated preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; zero shares issued and outstanding at June 30, 2026 and December 31, 2025
Common stock, $0.001 par value; 500,000,000 shares authorized at June 30, 2026 and December 31, 2025; 47,955,079 shares and 47,772,567 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively4848
Additional paid-in capital735,848719,287
Accumulated other comprehensive income (loss)(1,270)546
Accumulated deficit(311,700)(235,228)
Total stockholders’ equity422,926484,653

Item 1. Financial Statements.

FAQ

What is Rapport Therapeutics, Inc.'s common stock?
Rapport Therapeutics, Inc. (RAPP) reported common stock of $48K in Q2 2026.
How has Rapport Therapeutics, Inc.'s common stock changed year-over-year?
Rapport Therapeutics, Inc.'s common stock increased by 29.7% year-over-year, from $37K to $48K.
What is the long-term trend for Rapport Therapeutics, Inc.'s common stock?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s common stock has grown at a 246.4% compound annual growth rate (CAGR), from $4K to $48K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Rapport Therapeutics, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude